, Volume 29, Issue 1, pp 63–67 | Cite as

Affinity-purified human Interleukin I is cytotoxic to isolated islets of Langerhans

  • T. Mandrup-Poulsen
  • K. Bendtzen
  • J. Nerup
  • C. A. Dinarello
  • M. Svenson
  • J. H. Nielsen


Addition of highly purified human Interleukin-1 to the culture medium of isolated rat islets of Langerhans for 6 days led to 88% inhibition of glucose-induced insulin-release, reduction of islet contents of insulin and glucagon to 31% and 8% respectively, and disintegration of the islets. These effects were dose-dependent and reproducible when using three different Interleukin-1 preparations. Highly purified human Interleukin-2, Lymphotoxin, Leucocyte Migration Inhibitory Factor and Macrophage Migration Inhibitory Factor were ineffective. These findings suggest that Interleukin-1 may play an important role in the molecular mechanisms underlying autoimmune B-cell destruction leading to Type 1 (insulin-dependent) diabetes mellitus.

Key words

Autoimmunity pancreatic B cells cytotoxicity Interleukin-1 lymphokines macrophages pancreatic islets pathogenesis Type 1 (insulin-dependent) diabetes mellitus 


  1. 1.
    Nerup J, Lemmark A, Scott J (1984) Autoimmunity. In: Gupta S, ed: Immunology of clinical and experimental diabetes. Plenum Book Company, New York, pp 351–367Google Scholar
  2. 2.
    Rocklin RE, Bendtzen K, Greineder D (1980) Mediators of immunity: Lymphokines and monokines. Adv Immunol 29: 55–136PubMedCrossRefGoogle Scholar
  3. 3.
    Mandrup-Poulsen T, Bendtzen K, Nielsen JH, Bendixen G, Nerup J (1985) Cytokines cause functional and structural damage to isolated islets of Langerhans. Allergy 40: 424–429PubMedGoogle Scholar
  4. 4.
    Mandrup-Poulsen T, Bendtzen K, Nerup J, Egeberg J, Nielsen JH (1985) Mechanisms of pancreatic islet cell destruction: dose-dependent cytotoxic effect of soluble blood mononuclear cell mediators on isolated islets of Langerhans. Allergy (in press)Google Scholar
  5. 5.
    Brunstedt J (1980) Rapid isolation of functionally intact pancreatic islets from mice and rats by Percoll™ gradient centrifugation. Diabete Metab 6: 87–89PubMedGoogle Scholar
  6. 6.
    Heding L (1972) Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 8: 260–266PubMedCrossRefGoogle Scholar
  7. 7.
    Dinarello CA, Bernheim HA, Cannon JG, LoPreste G, Warner SJC, Webb AC, Anion PE (1985) Purified 35-S-methionine, 3-H-leucine labelled human monocyte interleukin-1 with endogenous pyrogen activity. Brit J Rheumatol 24: 59–64Google Scholar
  8. 8.
    Dinarello CA, Renfer L, Wolff SM (1977) Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Nail Acad Sci (USA) 74: 4623–4627Google Scholar
  9. 9.
    Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM, Dinarello CA (1984) Nucleotide sequence of human monocyte interleukin-1 precursor cDNA. Proc Natl Acad Sci (USA) 81: 7907–7911CrossRefGoogle Scholar
  10. 10.
    Robb RJ, Kutny RM, Chowdhry V (1983) Purification and partial sequence analysis of human T-cell growth factor. Proc Natl Acad Sci (USA) 80: 5990–5994CrossRefGoogle Scholar
  11. 11.
    Rhodes CJ, Taylor KW (1984) Effect of human lymphoblastoid interferon on insulin synthesis and secretion in isolated human pancreatic islets. Diabetologia 27: 601–603PubMedCrossRefGoogle Scholar
  12. 12.
    Dinarello CA (1984) Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med 311: 1413–1418PubMedCrossRefGoogle Scholar
  13. 13.
    Bendtzen K (1983) Biological properties of interleukins. Allergy 38:219–226PubMedGoogle Scholar
  14. 14.
    Giulian D, Lachman LB (1985) Interleukin-1 stimulation of astroglial proliferation after brain injury. Science 228: 497–499PubMedGoogle Scholar
  15. 15.
    Like AA, Forster RM, Woda BA, Rossini AA (1983) T-cell subsets in islets and lymphnodes of biobreeding/Worcester (BB/W) rats. Diabetes 32: 201 (Abstract)Google Scholar
  16. 16.
    Sibley RK, Sutherland DER, Goetz FC, Michael AF (1985) Recurrent diabetes mellitus in the pancreatic iso- and allograft period. A light and electronmicroscopic and immunohistochemical analysis of four cases. Lab Invest 53: 132–144PubMedGoogle Scholar
  17. 17.
    Debray-Sachs M, Boitard C, Assan R, Hamburger J (1981) Are “activated” macrophages cytotoxic against normal cells? Transpl Proc 13:1111–1113Google Scholar
  18. 18.
    Schwizer RW, Leiter EH, Evans R (1984) Macrophage-mediated cytotoxicity against cultured pancreatic islet cells. Transplantation 37:539–544PubMedGoogle Scholar
  19. 19.
    Oschilewski U, Kiesel U, Kolb H (1985) Administration of silica prevents diabetes in BB-rats. Diabetes 34:197–199PubMedGoogle Scholar
  20. 20.
    Nash JR, Everson NW, Wood RFM, Bell PRF (1980) Effect of silica and carrageenan on the survival of islet allografts. Transplantation 29: 206–208PubMedGoogle Scholar
  21. 21.
    Prud'homme GJ, Fuks A, Colle E, Seemayer TA, Guttmann RD (1984) Immune dysfunction in diabetes-prone BB-rats. Interleukin 2 production and other mitogen-induced responses are suppressed by activated macrophages. J Exp Med 159: 463–478PubMedCrossRefGoogle Scholar
  22. 22.
    Zier KS, Leo MM, Spielman RS, Baker L (1984) Decreased synthesis of interleukin-2 (IL-2) in insulin-dependent diabetes mellitus. Diabetes 33: 552–555PubMedGoogle Scholar
  23. 23.
    Luger A, Schernthaner G, Luger TA (1985) Lymphokine production in insulin-dependent diabetes mellitus. Eur J Clin Invest 15: 1 A (abstract)Google Scholar
  24. 24.
    Arenzana-Seisdedos FM, Virelizier JL (1983) Interferons as macrophage-activating factors II. Enhanced secretion of interleukin 1 by lipopolysaccharide-stimulated human monocytes. Eur J Immunol 13: 437–440PubMedGoogle Scholar
  25. 25.
    Bonner-Weir S, Orci L (1982) New perspectives on the microvasculature of the islets of Langerhans in the rat. Diabetes 31: 883–889PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • T. Mandrup-Poulsen
    • 1
  • K. Bendtzen
    • 2
  • J. Nerup
    • 1
  • C. A. Dinarello
    • 3
  • M. Svenson
    • 2
  • J. H. Nielsen
    • 4
  1. 1.Steno Memorial HospitalGentofteDenmark
  2. 2.Laboratory of Medical Immunology, RigshospitaletUniversity Hospital of CopenhagenCopenhagenDenmark
  3. 3.Department of MedicineTufts University School of MedicineBostonUSA
  4. 4.Hagedorn Research LaboratoryGentofteDenmark

Personalised recommendations